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Abbreviations: ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ASAT, 25 
aspartate aminotransferase; CAPN1, calpain 1; CAPN2, calpain 2; CAPN3, calpain 3; 26 
CAST, calpastatin; CAV3, caveolin 3; CDH15, cadherin 15; COXI, cytochrome c 27 
oxidase subunit I; CPT1A, carnitine palmitoyltransferase 1A; CS, citrate synthase; 28 
CTSB, cathepsin B; CTSD, cathepsin D; CTSL, cathepsin L; CTSS, cathepsin S; CUL2, 29 
cullin 2; CUL3, cullin 3; CUL5, cullin 5; DER-1, derlin-1; DES, desmin; DHA, 30 
docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; FAME, fatty acid 31 
methyl ester; FE, feed efficiency; FM, fish meal; FO, fish oil; FST, follistatin; GHR-I, 32 
growth hormone receptor I; GHR-II, growth hormone receptor II; GLDH, glutamate 33 
dehydrogenase; GRP-94, glucose-regulated protein, 94 kDa; GRP-170, glucose-34 
regulated protein, 170 kDa; Hb, haemoglobin; Hc, haematocrit; HDL, high density 35 
lipoprotein; HSI, hepatosomatic index; Hsp30, 30 kDa heat shock protein; Hsp90α, 90 36 
kDa heat shock protein alpha 1; Hsp90β, 90 kDa heat shock protein beta; IGF-I, insulin-37 
like growth factor-I; IGF-II, insulin-like growth factor-II; IGFALS, insulin-like growth 38 
factor-binding protein complex acid labile subunit; IGFBP1, insulin-like growth factor 39 
binding protein 1; IGFBP2, insulin-like growth factor binding protein 2; IGFBP4, 40 
insulin-like growth factor binding protein 4; IGFBP7, insulin-like growth factor binding 41 
protein 7; IGFR1, insulin-like growth factor receptor I; IGFR2, cation-independent 42 
mannose-6-phosphate receptor; IL-1β, interleukin-1 beta; IL-1R1, interleukin-1 beta 43 
receptor 1; IL-1R2, interleukin-1 beta receptor 2; IL-6, interleukin-6; IL-6RA, 44 
interleukin-6 receptor A; IL-6RB, interleukin-6 receptor B; IL-8, interleukin-8; IL-8RA, 45 
interleukin-8 receptor A; IL-10, interleukin-10; IL-10RA, interleukin-10 receptor A; IL-46 
10RB, interleukin-10 receptor B; INSR, insulin receptor; IGF-I, insulin-like growth 47 
factor-I; LC-PUFA, long chain polyunsaturated fatty acid; LDL, low density 48 
lipoprotein; LXRα, liver X receptor α; MEF2A, myocyte-specific enhancer factor 2A; 49 
MEF2C, myocyte-specific enhancer factor 2C; MET, c-met/hepatocyte growth factor 50 
receptor; MSI, mesenteric index; MSTN, myostatin; mtHsp10; 10 kDa heat shock 51 
protein, mitochondrial; mtHsp60, 60 kDa heat shock protein, mitochondrial; mtHsp70, 52 
70 kDa heat shock protein, mitochondrial; Myf5, myogenic factor 5; Myf6, myogenic 53 
factor 6; MyoD1, myoblast determination protein 1; MyoD2, myoblast determination 54 
protein 2; ND2, NADH-ubiquinone oxidoreductase chain 2; NDUFAF2, NADH 55 
dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 2; OXPHOS, 56 
oxidative phosphorylation; PAX7, paired box 7; PCNA, proliferating cell nuclear 57 
antigen; PGC1α, proliferator-activated receptor gamma coactivator 1 alpha; PPARα, 58 
peroxisome proliferator-activated receptor α; PPARγ, peroxisome proliferator-activated 59 
receptor γ; PSD12, 26S proteasome non-ATPase regulatory subunit 12; PSMA5, 60 
proteasome subunit alpha type-5; PSMB1, proteasome subunit beta type-1; PSMD4, 61 
26S proteasome non-ATPase regulatory subunit 4; RB, respiratory burst; RBC, red 62 
blood cells; RIA, radioimmunoassay; SCO1, SCO1 protein homolog mitochondrial; 63 
SGR, specific growth rate; SIRT1, sirtuin1; SIRT2, sirtuin2; SIRT3, sirtuin3; SIRT4, 64 
sirtuin4; SIRT5, sirtuin5; SOX3, transcription factor SOX3; TG, triglycerides; TNFα, 65 
tumor necrosis factor-alpha; TRADD, tumor necrosis factor receptor type 1-associated 66 
death domain protein; UBE2A, ubiquitin-conjugating enzyme E2 A; UBE2D2, 67 
ubiquitin-conjugating enzyme E2 D2; UBE2L3, ubiquitin-conjugating enzyme E2 L3; 68 
UBE2N, ubiquitin-conjugating enzyme E2N; UCHL3, ubiquitin carboxyl-terminal 69 
hydrolase isozyme L3; UCP1, uncoupling protein 1; UCP2, uncoupling protein 2; 70 
UCP3, uncoupling protein 3; VLDL, very low density lipoprotein; VO, vegetable oils; 71 
VSI, viscerosomatic index. 72 
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Abstract   74 
Four isoproteic/isolipidic plant protein-based diets were formulated to assess the lasting 75 
effects of feed additives and low fish meal (FM) and fish oil (FO) diet formulations on 76 
gilthead sea bream growth performance. FM was included at 23% in the control diet 77 
(D1) and at 3% in the other three diets (D2, D3, D4). Added oil was either FO (D1) or a 78 
blend of vegetable oils replacing 58% (D2) and 84% (D3, D4 diets) of FO. A 79 
commercial sodium butyrate preparation (NOREL, 70-BP) was added to the D4 diet at 80 
0.4%. Each diet was allocated to triplicate groups of juvenile fish fed to satiety over an 81 
8-month feeding trial (May-December). All fish grew efficiently from 15 g of initial 82 
body weight to 296–320 g with an overall feed efficiency (FE) of 0.95-1.01, although 83 
fish fed D3 and D4 diets showed transient growth impairments over the course of the 84 
first four weeks of the trial. Data on biometric indexes, whole body composition, 85 
haematology and blood biochemistry revealed a strong effect of sampling time in fish 86 
sampled at mid-summer (August) and late autumn (December). In contrast, the diet 87 
effect was mostly reduced to a few blood parameters. Low inclusion levels of FM 88 
reduced plasma haemoglobin levels (D2, D3), but these effects were reversed by 89 
butyrate supplementation (D4). The same phenomena occurred for total cholesterol with 90 
the highest circulating concentration of choline and IGF-I in fish fed the D4 diet during 91 
their summer growth spurt. At the transcriptional level, gene expression profiling of 92 
liver and skeletal muscle with a PCR-array of 87 growth markers provided additional 93 
evidence for an overall well-growth condition in all of the experimental groups. Up to 94 
73 genes were found at detectable levels in the liver tissue, but only 13 were 95 
differentially expressed. Likewise, 84 genes were actively transcribed in the skeletal 96 
muscle, but only nine were differentially expressed in at least one experimental group. 97 
Butyrate supplementation reversed the up-regulated expression of inflammatory 98 
cytokines (TNFα) and muscle markers of cellular morphogenesis and protein 99 
breakdown (CDH15, CAPN3, PSMA5, PSMB1, UBE2N) in the muscle of fish fed the 100 
extreme D3 diet. These results support the use of low FM/FO diets alone or 101 
supplemented with feed additives, which have the potential to improve or reverse 102 
metabolic steady-states. 103 
 104 
Keywords: fish meal, fish oil, butyrate, growth, blood biochemistry, molecular 105 
markers. 106 
Highlights:  107 
A very high replacement of fish meal and fish oil is highly feasible through the 108 
production cycle of gilthead sea bream.  109 
A short adaptive period with an intermediate diet is recommended when fish are fed 110 
diets with extremely low FM and FO diets. 111 
Data on haematology, blood biochemistry and growth rate regulated markers are 112 
indicative of a health-promoting action of dietary butyrate.  113 
  114 
1. Introduction 115 
 116 
The availability of wild fishery-derived raw materials is finite and the rapid and 117 
sustained growth rate of global aquaculture have forced the industry to explore 118 
alternative and more sustainable feed ingredients (Nasopoulou and Zabetakis, 2012; 119 
Tacon and Metian, 2008). Much attention has been focused on plant ingredients and 120 
there is now accumulating evidence for a large and combined replacement of FM and 121 
FO in a wide range of fish species of interest for European aquaculture. This includes 122 
Atlantic salmon (Bell et al., 2004; Pratoomyot et al., 2010; Torstensen et al., 2008), 123 
rainbow trout (Kaushik et al., 1995; Thanuthong et al., 2011), Atlantic cod (Jobling et 124 
al., 2008; Karalazos et al., 2007), turbot (Regost et al., 1999; 2003), European sea bass 125 
(Kaushik et al., 2004; Mourente and Bell, 2006) and gilthead sea bream (Benedito-Palos 126 
et al., 2007; 2009; Gómez-Requeni et al., 2004; Izquierdo et al., 2005). However, the 127 
long-term metabolic consequences of feeding very low FM and FO diets (with less than 128 
10% inclusion levels of raw marine ingredients) on metabolic programming at different 129 
developmental stages and on different fish species are still under debate. 130 
The nutritional and quality characteristics of edible fish matter are important 131 
aspects to consider (Nasopoulou and Zabetakis, 2012; Turchini et al., 2009). Certainly, 132 
high levels of n-3 LC-PUFA are important quality factors in human foods, and farmers 133 
are facing increasing pressures to include high levels of EPA (20:5n-3) and DHA 134 
(22:6n-3) in the finishing diets of salmonids and freshwater fish, which do not have 135 
specific requirements for n-3 LC-PUFA (Bell et al. 2004; Thanuthong et al. 2011). This 136 
is more evident in marine fish due to their limited capacity to elongate and desaturate 137 
C18 FAs into long chain C20 and C22 PUFAs. However, importantly, this metabolic 138 
constraint facilitates the multi-species predictive modelling of fillet FA composition 139 
year-round using a dummy regression approach with gilthead sea bream as the reference 140 
subgroup category (Ballester-Lozano et al., 2014a; 2014b). This tool is public 141 
accessible through an easy-to-use-web interface (www.nutrigroup-iats.org/aquafat) to 142 
guarantee a relatively high content of n-3 LC-PUFAs in marine fish meat, ensuring that 143 
the human health benefits of consuming farmed fish are retained (Larsen et al., 2011; 144 
Lund, 2013).  145 
Early growth studies have also proven that FO can be totally replaced by a blend 146 
of VOs in practical gilthead sea bream diets with a 35% inclusion level of FM 147 
(Bouraoui et al. 2011). Alternatively, up to 65–70% of FO can be replaced in diets with 148 
a 15–20% inclusion level of FM without detrimental effects or changes in growth 149 
performance (Benedito-Palos et al. 2007) or FA composition of phospholipids 150 
(Benedito-Palos et al. 2011), which are highly regulated to preserve cell integrity and 151 
function. However, to further proceed with low FM inclusion levels, fish feeds should 152 
be adequately fortified or supplemented with essential nutrients, which has generated 153 
increasing interest for natural feed additives and nutraceuticals in the industry. One 154 
example of this is butyrate, a short-chain FA that has received attention for its positive 155 
effect on gut health in several models of livestock animals (reviewed by Guilloteau et 156 
al., 2010). For instance, oral supplementation of microencapsulated sodium butyrate 157 
improves the immunological status and intestinal condition in common carp (Liu et al., 158 
2014). Similarly, a slight but significant growth improvement has been reported in 159 
gilthead sea bream with dietary butyrate supplementation (Robles et al., 2013). 160 
Recent progress has been achieved within the ARRAINA EU project to define 161 
reliable reference values for a set of biometric indexes, and biochemical, haematological 162 
and histochemical markers that have specificity, sensitivity and diagnostic value for the 163 
most common nutrient deficiencies arising from the replacement of FM and FO by 164 
alternative raw materials (Ballester-Lozano et al., 2015). At the molecular level, 165 
important advances have also been made on pathway-focused gene expression analyses 166 
using new genomic tools derived from the CSIC-nutrigroup transcriptomic database 167 
(www.nutrigroup.iats.org/seabream). Thus, gilthead sea bream PCR arrays are now 168 
available for wide transcriptional profiling of the intestine (Pérez-Sánchez et al., 2015) 169 
and mitochondria (Bermejo-Nogales et al., 2014b; 2015). Likewise, a set of growth rate 170 
regulated makers, including selected markers of the GH/IGF system (12), muscle 171 
growth and cell differentiation and proliferation (15), protein breakdown (20), protein 172 
folding and assembly (9), inflammatory and anti-inflammatory response (13), energy 173 
sensing (5), OXPHOS and mitochondrial respiration uncoupling (10), and master 174 
regulators of lipid metabolism (3), has recently been developed and validated for routine 175 
and clinical assessment of molecular signatures for growth in growing fish. This new 176 
tool together with more conventional biometric and biochemical markers of fish 177 
performance were used herein as part of the experimental setup to fully validate the use 178 
of extremely low FM and FO diets in gilthead sea bream. At the same time, the 179 
potential benefits of dietary butyrate supplementation at the lowest FM/FO inclusion 180 
level were explored, with attention focused on the metabolic and molecular profiling of 181 
blood, and liver and skeletal muscle as key target tissues for growth regulation at the 182 
systemic and peripheral level. 183 
 184 
 2. Materials and methods 185 
 186 
2.1. Diets 187 
 188 
Four isoproteic and isolipidic plant protein-based diets (1.9, 3, 4.5 mm extruded 189 
feeds), containing a blend of soya protein, corn gluten, wheat gluten, rapeseed cake, and 190 
wheat, were formulated and delivered by BioMar (Denmark). FM was included at 23% 191 
in the D1 (control) diet and at 3% in the other three experimental diets (D2, D3 and D4). 192 
Fish hydrolysate (CPSP) was added at 2% in all diets. Added oil was either FO (D1 193 
diet) or a blend of VOs (1:1 ratio of rapeseed oil: palm oil) replacing 58% (D2 diet) and 194 
84% (D3 and D4 diets) FO. A commercial butyrate preparation (NOREL, 70-BP) was 195 
added to the D4 diet at 0.4%. All diets contained histidine (0.14%), antioxidants 196 
(0.045%) and a mineral-vitamin mix (0.5%). Lysine, methionine, choline, lecithin and 197 
monocalcium phosphate were balanced in D2, D3 and D4 diets to the values of the 198 
control diet. The FA composition of experimental diets varied with the progressive FO 199 
replacement, decreasing on a dry matter basis the EPA (20:5n-3) plus DHA (22:6n-3) 200 
content from 2.9% (D1) to 1.38% (D2) and 0.6–0.7% (D3, D4) (Table 1).  201 
 202 
2.2. Feeding trial and sample collection  203 
Juvenile gilthead sea bream of Atlantic origin (Ferme Marine de Douhet, 204 
France) were acclimatised for four weeks to the indoor experimental facilities of the 205 
Institute of Aquaculture Torre de la Sal (IATS, Spain). During this initial period, fish 206 
were fed with a standard diet (Efico YM 568 1.9 mm, BioMar). Then, fish of 13–16 g 207 
initial mean body weight were distributed in 2500 L tanks in triplicate groups of 180 208 
fish each. Oxygen content of outlet water remained higher than 75% saturation, and 209 
day-length and water temperature followed the natural changes at IATS latitude (40º 210 
5’N; 0º 10’E). Each experimental diet was offered to visual satiety 1–2 times per day 211 
and 3–6 days per week from May 2013 to December 2013 (8-month feeding trial), 212 
according to the changes in fish size and season. Feed intake was recorded weekly and 213 
fish were counted and group-weighed every 4–6 weeks. No significant mortalities (less 214 
than 0.5%) were registered regardless of dietary treatment.  215 
At weeks 13 (August) and 31 (December), overnight fasted fish (4 fish per tank, 216 
12 per experimental condition) were randomly sampled and anaesthetised with 3-217 
aminobenzoic acid ethyl ester (MS-222, 0.1 g/l) for blood and tissue collection. Blood 218 
was quickly drawn from caudal vessels with heparinized syringes. One aliquot was used 219 
for haematological measurements. The remaining blood was centrifuged at 3,000 g for 220 
20 min at 4ºC, and plasma samples were frozen and stored at -20ºC until biochemical 221 
assays. Prior to tissue collection, fish were killed by cervical section, and liver, viscera 222 
and mesenteric fat were weighed. Liver and a dorsal muscle portions were rapidly 223 
harvested, frozen in liquid nitrogen and stored at -80ºC until RNA isolation. Additional 224 
specimens of fish (a pool of 10 fish at the beginning and pools of 4 fish per tank at 225 
weeks 13 and 31) were ground for whole body composition analyses. 226 
All procedures were carried out according to the national (IATS-CSIC Review 227 
Board) and present EU legislation on the handling of experimental animals. 228 
 229 
2.3. Chemical analyses 230 
 231 
The proximate composition of diets and whole fish were analysed by standard 232 
procedures (AOAC, 2005). Moisture content was determined by drying in an oven at 233 
105ºC for 24 h. Diets and freeze-dried triturated fish were blended and used for protein 234 
and lipid analyses. Lipid content (from 0.5 g samples) was determined gravimetrically 235 
by the Soxhlet method using 50 ml diethyl ether at 120ºC as the extracting solvent 236 
(Soxhlet 4001046 Auto extraction apparatus; Selecta, Barcelona, Spain). Protein content 237 
(N x 6.25) was determined using the automated Kjeldhal method (Kjeldhal Auto 238 
4002430 Analyser, Selecta).  239 
 240 
  241 
2.4. Blood haematology and biochemistry  242 
 243 
Hb concentration was determined with a HemoCue B-Haemoglobin Analyser® 244 
(AB, Leo Diagnostic, Sweden), which uses a modified azide methaemoglobin reaction 245 
for Hb quantification. The Hc was measured after centrifugation of blood in heparinised 246 
capillary tubes at 13,000 g for 10 min. Counts of RBC were made in a Neubauer 247 
chamber, using an isotonic solution (1% NaCl). 248 
Plasma glucose was measured by the glucose oxidase method according to 249 
manufacturer’s instructions (ThermoFisher Scientific, Waltham, Massachusetts, USA). 250 
Plasma TGs were determined using lipase/glycerol kinase/glycerol-3-phosphate oxidase 251 
reagent. Total plasma cholesterol was determined using a cholesterol 252 
esterase/cholesterol dehydrogenase reagent (ThermoFisher Scientific). HDL and 253 
LDL/VLDL cholesterol were determined with the EHDL-100 kit from BioAssay 254 
Systems (Hayward, California, USA), based on an improved polyethylene glycol 255 
precipitation method in which HDL and LDL/VLDL are separated, and cholesterol 256 
concentrations are determined using cholesterol esterase/cholesterol dehydrogenase 257 
reagent. Total plasma proteins were measured with the Bio-Rad protein reagent 258 
(Hercules, California, USA) with bovine serum albumin as standard.  259 
Changes in plasma enzyme activities of ALAT (EC 2.6.1.2), ASAT (EC 2.6.1.1) 260 
and GLDH (EC 1.4.1.2) were measured using colorimetric assay kits (EALT-100, 261 
EASTR-100, DGLDH-100; BioAssays Systems). Plasma ALP (EC. 3.1.3.1) activity 262 
was determined by a fluorimetric assay kit (QFAP-100, BioAssays Systems). 263 
Plasma levels of creatinine (DICT-500), choline (ECHO-100), calcium (DICA-264 
500), chloride (DICL-250), magnesium (DMG-250) and phosphate (DIPI-500) were 265 
measured by colorimetric assay kits (BioAssays Systems). Total antioxidant capacity 266 
was measured as Trolox activity using a microplate assay kit (709001) (Cayman 267 
Chemical, Ann Arbor, Michigan, USA). Plasma lysozyme activity was measured by a 268 
turbidimetric assay adapted to microplates (Sitjà-Bobadilla et al., 2005). Induction of 269 
the RB activity in blood leukocytes was measured directly from heparinised blood, 270 
following the method described by Nikoskelainen et al. (2005) with some modifications 271 
(Saera-Vila et al., 2009a).  272 
Plasma GH was determined by a homologous gilthead sea bream RIA as 273 
reported elsewhere (Martínez-Barberá et al., 1995). The sensitivity and midrange 274 
(ED50) of the assay were 0.15 and 1.8 ng/ml, respectively. Plasma IGFs were extracted 275 
by acid-ethanol cryoprecipitation, and the concentration of IGF-I was measured by 276 
means of a generic fish IGF-I RIA validated for Mediterranean perciform fish (Vega-277 
Rubín de Celis et al., 2004). The sensitivity and midrange of the assay were 0.05 and 278 
0.7–0.8 ng/ml, respectively. 279 
 280 
2.5. RNA extraction and reverse transcription 281 
 282 
Total RNA from liver and skeletal muscle was extracted with a MagMAX-96 283 
total RNA isolation kit (Life Technologies, Carlsbad, CA, USA). RNA yield was 50–284 
100 µg with UV absorbance measures (A260/280) of 1.9–2.1 and RIN (RNA integrity 285 
number) values of 8–10, as measured on an Agilent 2100 Bioanalyser, which is 286 
indicative of clean and intact RNA. Reverse transcription of 500 ng of total RNA was 287 
performed with random decamers, using the High-Capacity cDNA Archive Kit 288 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 289 
instructions. Negative control reactions were run without reverse transcriptase. 290 
 291 
2.6. Gene expression analyses 292 
 293 
Real-time quantitative PCR was carried out with an Eppendorf Mastercycler Ep 294 
Realplex real-time PCR system (Eppendorf, Wesseling-Berzdorf, Germany), using a 295 
96-well PCR array layout designed for the simultaneously profiling of a panel of 87 296 
growth rate regulated genes (Table S1), selected as markers of: i) GH/IGF system: 297 
GHR-I, GHR-II, IGF-I, IGF-II, IGFBP1, IGFBP2, IGFBP4, IGFBP7, IGFALS, INSR, 298 
IGFR1, and IGFR2; ii) muscle growth and cell differentiation and proliferation: 299 
MyoD1, MyoD2, Myf5, Myf6, MSTN, MEF2A, MEF2C, FST, CAV3, DES, CDH15, 300 
PCNA, PAX7, SOX3, and MET; iii) protein breakdown: CAPN1, CAPN2, CAPN3, 301 
CAST, CTSB, CTSD, CTSL, CTSS, PSMD4, PSD12, PSMA5, PSMB1, UCHL3, 302 
UBE2A, UBE2D2, UBE2L3, UBE2N, CUL2, CUL3, and CUL5; iv) protein folding 303 
and assembly: mtHsp10, Hsp30, mtHsp60, mtHsp70, Hsp90α, Hsp90β, GRP-170, GRP-304 
94, and DER-1; v) inflammatory/anti-inflammatory response: IL-1β, IL-1R1, IL-1R2, 305 
IL-6, IL-6RA, IL-6RB, IL-8, IL-8RA, IL-10, IL-10RA, IL-10RB, TNF-α, and TRADD; 306 
vi) energy sensing: SIRT1, SIRT2, SIRT3, SIRT4, SIRT5; vii) OXPHOS: PGC1α, 307 
CPT1A, CS, ND2, NDUFAF2, COXI, and SCO1; viii) mitochondrial respiration 308 
uncoupling: UCP1, UCP2, and UCP3 and ix) lipolytic/lipogenic transcription factors: 309 
LXRα, PPARα, and PPARγ. The array included 34 new sequences for gilthead sea 310 
bream, already represented in the sea bream transcriptomic database (www.nutrigroup-311 
iats.org/seabreamdb) and uploaded to GenBank with the accession numbers 312 
KM522771–KM522804. Among them, eighteen are full codifying sequences varying in 313 
length from 444 to 2235 nucleotides (Table S2).  314 
Housekeeping genes and controls for general PCR performance were included 315 
on each array, and all the pipetting operations were performed with the EpMotion 5070 316 
Liquid Handling Robot (Eppendorf) as reported previously in the same fish species for 317 
pathway-focused PCR arrays of intestine (Pérez-Sánchez et al., 2015), mitochondria 318 
(Bermejo-Nogales et al., 2014b; 2015) and immune-relevant genes (Pérez-Cordón et al., 319 
2014). The specificity of reactions was verified by analysis of melting curves (ramping 320 
rates of 0.5ºC/10 s over a temperature range of 55–95ºC) and linearity of serial dilutions 321 
of RT reactions. Fluorescence data acquired during the PCR extension phase were 322 
normalised using the delta-delta Ct method (Livak and Schmittgen, 2001). β-actin was 323 
used as the housekeeping gene in the normalisation procedure. Technical replicates of 324 
samples were run initially to test the reproducibility of the array, but the obtained data 325 
had a very high reproducibility score and technical plate replicates were finally omitted. 326 
For multi-gene analysis comparisons, relative gene expression was referenced on each 327 
tissue to the expression level of IGFR2 of control fish (D1 diet) with an arbitrarily 328 
assigned value of 1. Data of fold-change were relative to control fish (values > 1, up-329 
regulated genes in fish fed D2/D3/D4 diets; values < 1, down-regulated genes in fish fed 330 
D2/D3/D4 diets). 331 
 332 
2.7. Statistical analysis 333 
 334 
Data on growth performance, organosomatic indexes, whole body composition, 335 
blood biochemistry and gene expression were analysed by one- and two-way ANOVA 336 
(with diet and sampling time as variable factors) at a significance level of 5%. All 337 
analyses were made using the IBM SPSS Statistics package version 19 (Armonk, NY: 338 
IBM Corp.). 339 
  340 
  341 
3. Results 342 
 343 
3.1. Growth performance 344 
 345 
All fish in the trial grew efficiently from an initial body weight of 15 g to 296–346 
320 g (Figure 1) with overall FE of 0.95–1.01 and SGR of 1.37–1.42% (Table 2). Fish 347 
fed D1 and D2 diets were undistinguishable in terms of growth and feed efficiency for 348 
almost all of the experimental period. However, fish fed with the lowest FO inclusion 349 
level (D3 and D4 diets) showed an impaired FE in comparison to the control group 350 
(0.96 vs. 0.60-0.62 for D1 and D3-D4, respectively) over the course of the first four 351 
weeks of the trial. This detrimental effect was partially reversed thereafter and only a 352 
slight (6–7%) reduction in body weight was found at the last recording sampling time 353 
(December).  354 
Biometric data in Table 3 indicates that VSI and MSI indexes (calculated as the 355 
ratio of organ weight to fish weight) decreased with fish size when comparisons were 356 
made between fish sampled in summer (August) and late autumn (December). In 357 
contrast, HSI increased with the increase of fish size during the cold season. Dietary 358 
treatment did not have significant effects on organosomatic indexes, although the 359 
highest HSI was reported in D3 fish (P = 0.051) and a partial recovery was observed 360 
with butyrate supplementation (D4 fish). Whole body composition remained almost 361 
unaltered by dietary treatment, although a pronounced increase in either protein (from 362 
16% to 18%) or lipid (from 9% to 12%) content was found from August to December, 363 
regardless of fish feed. 364 
 365 
3.2. Blood analyses  366 
 367 
Two-way analysis of variance revealed a sampling-time effect (August 2013 vs. 368 
December 2013) for most of the analysed parameters (Table 4). In contrast, a diet effect 369 
(P < 0.05) was mostly reduced to Hb concentration, counts of RBC and plasma levels of 370 
cholesterol, choline and IGF-I. Noticeably, significant Diet x Time interactions were 371 
shown for most of these parameters indicating that the dietary effects were dependent 372 
on the time of sampling. Overall, low FM inclusion levels reduced Hb concentration in 373 
fish fed D2 and D3 diets, but butyrate feed supplementation reversed this effect in fish 374 
fed the D4 diet in the second sampling. A similar trend was shown for total plasma 375 
cholesterol levels. In summer, this metabolic feature was linked to the rise of HDL 376 
cholesterol, whereas in December it was linked to the increase of plasma levels of 377 
VLDL/LDL cholesterol. Fish fed the D4 diet showed the highest plasma concentration 378 
of choline and IGF-I at the summer sampling time (fast growing period), but no 379 
differences were shown in the winter sampling (Diet x Time interaction P < 0.05). Total 380 
cholesterol, choline and IGF-I were strongly affected by sampling time showing 30-381 
75% increase in total cholesterol and 50% reduction in choline and IGF-I levels 382 
between August and December irrespective of the dietary treatment. 383 
 384 
3.3. Liver and muscle gene expression profiling 385 
 386 
Results of gene expression profiling are summarized as Tables S4 and S5. In the 387 
liver tissue, up to 73 genes included in the array were found at detectable levels (Table 388 
S4). Among them, 13 were differentially expressed in response to dietary treatment. 389 
Relative expression of IGF-I was significantly reduced in D3 fish in comparison to the 390 
control group, but this effect was partially reversed by butyrate supplementation in D4 391 
fish. Conversely, the expression of a proliferative cell marker (PCNA) was significantly 392 
reduced in the D4 group, but not in the D2 and D3 groups. Overall, the expression of 393 
molecular chaperones (mtHsp10, mtHsp60, mtHsp70, Hsp90β) was significantly 394 
reduced in D2, D3 and D4. The same trend was observed for receptors of inflammatory 395 
(IL-6RB, TRADD) and anti-inflammatory (IL-10RB) cytokines, markers of oxidative 396 
metabolism (CS, COXI) and transcription factors with a lipolytic (LXRα) or lipogenic 397 
role (PPARγ). For an easier interpretation of these results, data relative to fold-changes 398 
of differentially expressed genes is shown in Figure 2A. 399 
In the skeletal muscle, 83 out of 87 genes present in the array were actively 400 
transcribed (Table S5, but only 9 genes were differentially expressed in at least one 401 
experimental group (fold-changes of differentially expressed genes are shown in Figure 402 
2B). Most of the changes in gene transcription were related to intercellular adhesion 403 
glycoproteins (CDH15) and protein-breakdown markers of the calpain/calpastatin 404 
system (CAPN3) and ubiquitin-proteasome pathway (PSMA5, PSMB1, UCHL3, 405 
UBE2N) with the highest expression in fish fed the D3 diet and a recovery of control 406 
values with butyrate supplementation in fish fed the D4 diet. At the same time, the 407 
expression of the catabolic/lipolytic cytokine TNFα was significantly reduced in D4 fish 408 
in comparison to fish fed the D3 diet with intermediate values in control and D2 fish. 409 
The trend for PPARα and PPARγ was a progressive down-regulated expression with the 410 
FM/FO replacement, which was exacerbated with butyrate supplementation, since 411 
significant differences were only found between D1 and D4 groups. 412 
 413 
4. Discussion  414 
 415 
 In the present study, the long term effects of concurrent and high substitution of 416 
FM and FO in gilthead sea bream diets were evaluated. In particular, gilthead sea bream 417 
growing from 15 g to approximately 300 g showed very good overall growth 418 
performance and feed utilization even when fed diets containing as little as 3% total FM 419 
and 2.5% FO. Feeding trials conducted within the AQUAMAX EU Project (2006-2010) 420 
indicated that a combined and partial replacement of FM and FO is highly feasible in 421 
gilthead sea bream when the theoretical requirements of essential nutrients are met by 422 
diet. In these studies, the threshold level for marine feedstuffs was fixed at 25% (with 423 
FM level at 20%) on the basis of growth criteria and histopathological scoring of liver 424 
and intestine tissue samples (Benedito-Palos et al., 2007; 2008; 2009). Current studies 425 
within the ARRAINA EU Project (2012-2016) indicate that histopathological signs of 426 
liver and intestine damage were not found in any experimental group when 427 
experimental diets were adequately balanced to the control diet in terms of macro and 428 
micro-nutrients (Estensoro et al., 2014). Nevertheless, when comparisons are made 429 
among groups, the results presented herein highlighted a slight impairment of growth 430 
performance and feed utilization (reduced weight, SGR and FE) at the beginning of the 431 
experiment with the decrease of marine ingredients in the diets. This adverse effect was 432 
almost completely reversed through the first year of the production cycle (8-month 433 
feeding trial) in terms of SGR and FE although, the lower performance in the first 434 
period reflected in fish weight throughout the trial. These findings highly support a 435 
trend of good growth in all experimental groups, although a short adaptive feeding 436 
period with intermediate diets, like D2, should be given prior the use of extremely low 437 
FM/FO diets (less than 10% marine ingredients) on intensive marine fish farming. 438 
The GH/IGF system is one of the most important endocrine determinants of 439 
growth in a vast array of stress and nutritional disorders arising in gilthead sea bream 440 
from crowding and handling stress (Rotllant et al., 2001; Saera-Vila et al., 2009b) or 441 
changes in ration size and diet composition (Pérez-Sánchez et al., 1995; Gómez-442 
Requeni et al., 2004; Benedito-Palos et al., 2007). It is noteworthy that gene expression 443 
profiling of liver and skeletal muscle with selected markers of growth, including GH 444 
receptors, IGFs, IGF binding proteins, insulin receptors, and IGF receptors, highlighted 445 
almost the same molecular signatures for all the groups in the trial when fish were 446 
sampled during the fast growing period for this species at our latitude. The unique 447 
exception is the hepatic IGF-I, which was significantly down-regulated in D3 fish in 448 
comparison to control fish. This observation was correlated, at the protein level, with 449 
low circulating levels of IGF-I, with a summer rebound effect brought about by butyrate 450 
supplementation in fish fed the D4 diet. Despite this, overall growth performance was 451 
almost the same in all experimental groups, which is perhaps indicative of 452 
overlapping/compensatory effects of growth factors at the hepatic, systemic or 453 
peripheral level. In previous feeding trials, we also failed to have a significant 454 
improvement of weight gain or FE when butyrate (BP-70) was added at a broad range 455 
(0.2–0.9%) in gilthead sea bream feeds with 20% FM and 10% FO (Pérez-Sánchez et 456 
al., 2013). However, a 5% increase in weight gain was reported by Robles et al. (2013) 457 
in an 8-week feeding trial with the addition of 0.3% butyrate in 15% FM and 7.2% FO 458 
diets. Likewise, controversial and sometimes negative results have been reported in 459 
other fish species, such as carp (Liu et al., 2014), trout (Gao et al., 2011) and salmon 460 
(Bjerkeng et al., 1999). However, as reported below, butyrate had some direct or 461 
indirect effects on a series of metabolic traits, which might be indicative of changes on 462 
nutrient requirements for an adequate overall fish performance.  463 
The hypocholesterolemic effect of plant proteins has been observed in a wide 464 
range of fish species, including gilthead sea bream (Gómez-Requeni et al., 2004), 465 
European sea bass (Messina et al., 2013), trout (Romarheim et al., 2008), salmon 466 
(Hartviksen et al., 2014), and tiger puffer (Lim et al., 2011). Likewise, feeding trials 467 
conducted by us with semi-synthetic diets highlighted that FO replacement with VOs 468 
acts to lower TG and cholesterol factors in gilthead sea bream (Ballester-Lozano et al., 469 
2015). In the same study, diets formulated for deficiencies in phospholipids and 470 
vitamins also showed a hypocholesterolemic effect, whereas phosphorus deficient diets 471 
had a hypercholesterolemic effect in gilthead sea bream. A hypocholesterolemic effect 472 
of VOs has also been reported for FM-based diets in Atlantic salmon (Jordal et al., 473 
2007) and black sea bream (Peng et al., 2008). No effects on plasma cholesterol levels 474 
were found in European sea bass and trout using soybean oil diets (Figueiredo-Silva et 475 
al., 2005), but a hypocholesterolemic effect was reported by other authors with the use 476 
of a blend of VOs containing linseed oil, palm oil and rapeseed oil (Richard et al. 477 
2006a; 2006b). Additionally, experimental evidence in trout (Norambuena et al., 2013) 478 
and salmon (Kortner et al., 2014) indicates that fish actively produce cholesterol as an 479 
structural component of cell membranes and as a precursor of bile acids and steroid 480 
hormones, adjusting their cholesterol production to dietary cholesterol loads. In the 481 
present study, all diets were supplemented with a fixed amount of cholesterol (0.113%), 482 
but we observed a cholesterol lowering effect that was especially evident with the 483 
maximum replacement of FM and FO in fish fed the D3 diet in winter. However, this 484 
apparently negative effect was completely reversed by butyrate feed supplementation in 485 
fish fed the D4 diet. There is no literature directly related to this, but it is interesting to 486 
note that butyrate is able to regulate lipoprotein metabolism, which is closely related to 487 
cholesterol metabolism (Marcil et al., 2002; Nazih et al., 2001).  488 
From our results, we can conclude that low FM inclusion levels in diets D2 and 489 
D3 were related to a statistically significant reduction in circulating Hb concentration, 490 
but, importantly, this effect was reversed by dietary butyrate supplementation. In 491 
humans, butyrate was able to induce fetal Hb production in patients with Hb disorders 492 
(Atweh et al., 1999; Fathallah et al., 2007). In vitro studies also showed a positive 493 
modulation of Hb-A synthesis by butyrate in congenital haemolytic anaemia (Reinhardt 494 
et al., 2001). Moreover, short chain FAs promoted absorption of minerals (calcium, 495 
magnesium and iron) clinically relevant for the treatment and prevention of certain 496 
diseases such as anaemia and osteoporosis in humans (Teitelbaum and Walker, 2002). 497 
However, the effects of butyrate supplementation on the circulating Hb concentration 498 
have not been yet investigated in fish. Therefore, the results presented here support new 499 
potential benefits of fish feed additives in order to improve the overall health and 500 
welfare condition of livestock fish, which might be related to iron metabolism.  501 
Another effect of dietary butyrate supplementation was the increase of 502 
circulating choline levels in fish sampled during the summer growth spurt. Choline is a 503 
water-soluble vitamin compound needed for the structural integrity and signalling roles 504 
of cell membranes and cholinergic neurotransmission (acetylcholine synthesis). Choline 505 
also acts as a major source of methyl groups via its metabolite trimethylglycine 506 
(betaine), which participates in the S-adenosyl methionine synthesis pathway (Glier et 507 
al., 2014; Miller, 2002). Therefore, choline is considered an essential nutrient for fish 508 
(NRC, 1993) that improves growth, digestive and absorptive capacities, and antioxidant 509 
defences, enhancing disease resistance and immune function (Mai et al., 2009; Wu and 510 
Davis, 2005; Wu et al., 2011; 2013; 2014). All diets were balanced in choline content 511 
but, interestingly, the highest plasma concentration in the summer sampling point was 512 
achieved with dietary butyrate supplementation while no differences were shown 513 
between the control diet (D1) and D2 or D3 as well as between all treatments in winter. 514 
Whether the increase in the summer is indicative of a better metabolic condition as a 515 
result of changes in endogenous choline synthesis, nutrient absorption, or consumption 516 
rates remains unclear from a functional and mechanistic point of view. 517 
At the molecular level, it is worth noting that the expression of mitochondrial 518 
and cytoplasmic chaperones (mtHsp10, mtHsp60, mtHsp70, Hsp90β) were down-519 
regulated in the liver tissue of D2, D3, and D4 fish groups. It is possible that these 520 
changes might elicit an improved protein-folding capacity in control fish, which might 521 
be indicative of a healthy metabolic condition. Experimental evidence in gilthead sea 522 
bream indicates that mitochondrial activity and biogenesis are highly regulated by 523 
nutritional and environmental stressors (Calduch-Giner et al., 2014; Bermejo-Nogales et 524 
al., 2015; 2014a; 2014b; 2008), and either mtHsp60, mtHsp70 or Hsp90 are considered 525 
highly valuable health markers in a vast array of metabolic disorders. Strong support for 526 
this notion comes from inbreeding selection of rat strains with “lower power” vs. “high 527 
power” mitochondria, which demonstrates that most stress and risk factors segregate 528 
with low expression levels of genes required for mitochondria biogenesis and oxidative 529 
phosphorylation (Wisløff et al., 2005). Alternatively, this might also represent a risk 530 
factor contributing to hepatic steatosis development. Indeed, the decrease in 531 
mitochondrial oxidative capacity might be the result of an imbalance between fat 532 
oxidation and lipogenesis, leading to hepatic fat accumulation in the human syndrome 533 
of non-alcoholic fat liver diseases (Byrne, 2010). In our model, this metabolic risk 534 
factor is further supported by the down-regulated expression of some mitochondrial 535 
catabolic genes (CS, COXI) in combination with the depressed expression of 536 
transcriptional master regulators of lipolysis (LXRα) and lipogenesis (PPARγ), which 537 
would suggest different allostatic steady-states in fish fed the control diet and fish fed 538 
the other three experimental diets. In any case, as reported above, no signs of 539 
histopathological damage have been reported in any experimental group, although there 540 
was a tendency for higher HSI in fish fed the D3 diet, with a recovery of control values 541 
in fish given the butyrate supplement. 542 
Other transcriptionally-mediated effects were related to the up-regulated 543 
expression of CDH15 in the muscle tissue of fish fed with the extremely low FM/FO 544 
diet (D3). This muscle cadherin is essential for the control of morphogenetic processes, 545 
specifically myogenesis, and provides a trigger for terminal muscle cell differentiation 546 
with an up-regulated expression in myotube-forming cells, which have been recognized 547 
as part of the mechanisms related to the increase of muscle protein mass as a whole 548 
(Donalies et al. 1991). In our case, this occurred in conjunction with the up-regulation 549 
of calpain 3 and protein markers of the Ub-proteasome pathway (PSMA5, PSMB1, 550 
UBE2N), which is prone to increased proteolysis and, thereby, protein turnover. This 551 
provides an essential quality control mechanism that selectively eliminates abnormally 552 
folded or damaged proteins that have arisen due to biosynthetic errors, damage by 553 
oxygen radicals, or by denaturation (especially at high temperatures). Protein turnover is 554 
specifically augmented with the net increase of protein accretion rates in humans, 555 
rodents and livestock fish, including gilthead sea bream (Houlihan et al., 1993). This 556 
offers the possibility of a stricter quality control system with the rise of growth rates, 557 
theoretically increasing the immediate disposal of essential amino acids for protein 558 
synthesis. In sepsis, certain types of cancer, and burn injuries, the enhancement of the 559 
Ub-proteasome pathway appears to be signalled by cytokines (IL-1, TNFα) released 560 
from activated macrophages (Holecek, 2012; Merritt et al., 2012). In our case, the 561 
relative muscle gene expression of several ILs and IL-receptors was not altered by the 562 
dietary intervention, but the up-regulated expression of TNF-α in D3 fish might elicit 563 
the activation of muscle protein catabolism in these fish. These transcriptional changes 564 
of muscle protein metabolism were not found with the butyrate diet and the muscle gene 565 
expression pattern of D4 fish, at least for myogenic and muscle protein breakdown 566 
markers, was related to the control group rather than D3 fish. This provides further 567 
evidence for a vast array of metabolic effects that short FAs might have on the 568 
regulation of fish metabolism, but the ultimate consequences on sensorial flesh quality 569 
remain to be discovered.  570 
 571 
5. Conclusions 572 
  573 
Data on growth performance, and blood haematology and biochemistry clearly 574 
indicate that a very high level of FM and FO replacement is feasible when the 575 
theoretical requirements for essential nutrients are met by the diet. However, with the 576 
most extreme diet composition (D3, 3% FM & 2.5% FO), an adaptive period may be 577 
necessary to avoid initial and transient detrimental effects on growth performance. 578 
Apparently, butyrate supplementation did not alter this time course, although it was able 579 
to restore blood levels of Hb and cholesterol. Other butyrate-mediated effects included 580 
an increased circulating concentration of choline and IGF-I over the course of the 581 
summer growth spurt. Molecular signatures of growth rate-regulated genes remained 582 
almost unaltered with the FM/FO replacement, providing further evidence of suitable 583 
growth conditions in all experimental groups. However, it is noteworthy that butyrate 584 
supplementation was able to reverse the increased expression of inflammatory cytokines 585 
and muscle markers of cellular morphogenesis and protein breakdown in fish fed the 586 
extreme FM/FO diet. In contrast, at the hepatic level, the transcription-mediated 587 
changes in molecular chaperones, oxidative enzymes, immune-relevant genes, and 588 
master regulators of lipid metabolism were not returned to control values by dietary 589 
butyrate supplementation. Taken together, our results support the use of low FM/FO 590 
fish feeds alone or supplemented with feed additives, although a different steady-state 591 
level was observed for some of the analysed parameters.  592 
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  917 
Figure legends 918 
 919 
Figure 1. (A) Seasonal changes of temperature (solid line) and day length (dash line). 920 
(B) Body weight over the course of the trial of fish fed experimental diets; arrows 921 
indicate tissue sampling times. Values are the mean of triplicate tanks. 922 
 923 
Figure 2. (A) Fold-changes (experimental/ control group) of differentially expressed 924 
genes (P < 0.05) in the liver tissue. (B) Fold-changes (experimental/control group) of 925 
differentially expressed genes (P < 0.05) in skeletal muscle. Values > 1 indicate up-926 
regulated genes in fish fed the experimental diets (D2, D3, D4); values < 1 indicate 927 
down-regulated genes in fish fed the experimental diets (D2, D3, D4). 928 
 929 
 930 




































Supplied the following (g/kg mix, except as noted): calcium 689, sodium 
108, iron 3, manganese 1, zinc 1, cobalt 2 mg, iodine 2 mg, selenium 20 
mg, molybdenum 32 mg, retinyl acetate 1, DL-cholecalciferol 2.6, DL-α 
tocopheryl acetate 28, menadione sodium bisulphite. Ascorbic acid 16, 
thiamin 0.6, riboflavin 1.7, pyridoxine 1.2, vitamin B12 50 mg, nicotinic 
acid 5, pantothenic acid 3.6, folic acid 0.6, biotin 50 mg. 
2 
Contains methionine, lysine, choline, lecithin 
  
Ingredient (%) Diet 
 D1 D2 D3 D4 
Fish meal 23.0 3.0 3.0 3.0 
Fish hydrolysate (CPSP) 2.0 2.0 2.0 2.0 
Soya protein 16.0 25.0 25.0 25.0 
Corn gluten 15.0 25.0 25.0 25.0 
Wheat gluten 4.00 7.30 7.30 7.30 
Rapeseed cake 12.00 9.70 9.90 9.90 
Wheat 11.08 6.80 6.64 6.24 
Fish oil 15.60 6.56 2.50 2.50 
Rapeseed oil 0 4.40 6.50 6.50 
Palm olein 0 4.40 6.50 6.50 
Monocalcium phosphate 0.303 2.097 2.097 2.097 
Histidine 0.136 0.136 0.136 0.136 
Mineral-vitamin mix
1
 0.500 0.500 0.500 0.500 





0.20 2.92 2.74 2.74 
Antioxidants 0.045 0.045 0.045 0.045 
Yttrium 0.03 0.03 0.03 0.03 
BP-70 0 0 0 0.40 
     
Proximate composition     
Dry matter (DM, %) 91.65 91.79 91.80 92.34 
Crude protein (% DM) 45.48 46.73 46.12 46.03 
Crude fat (% DM) 19.80 19.56 20.13 19.40 
EPA+DHA (% DM) 2.90 1.38 0.67 0.63 
Table 2. Growth performance of juvenile gilthead sea bream fed the experimental diets 
from May to December (31 weeks).  
Values are the mean ± SEM of dietary triplicates. Different column superscript letters indicate significant 
differences within each experimental period (Holm-Sidak test, P<0.05). 
1
Specific growth rate = 100 x (ln final weight – ln initial weight)/days 
2
Feed efficiency = weight gain/feed intake 
 
Diet Mean body weight  Weight SGR (%)1 Feed intake FE2 
 Initial Final  gain (%)  (g dry/fish)  
Week 4 (May-June) 
D1(FM23/FO15) 
Q
15.0±0.04 23.7±0.12a  58.2±1.1a 1.70±0.01a 9.03±0.25 0.96±0.06a 
D2(FM3/FO6) 
1
15.3±0.05 22.9±0.20a  49.9±0.2b 1.50±0.02b 9.05±0.15 0.84±0.03b 
D3(FM3/FO2.5) 
1
15.2±0.03 20.5±0.13b  34.3±0.45c 1.09±0.01c 8.77±0.18 0.60±0.04c 
D4(FM3/FO2.5/BUT) 
1
15.4±0.04 20.9±0.21b  36.1±0.5c 1.14±0.03d 9.01±0.34 0.62±0.02c 
        
Week 13 (June-August)      
D1(FM23/FO15) 23.7±0.12a 
8
87.6±0.87a  272.1±3.71 2.08±0.01 54.8±1.16 1.15±0.09 
D2(FM3/FO6) 22.9±0.20a 
1
82.7±0.04ab  256.7±0.24 2.01±0.01 53.4±0.49 1.1±0.01 
D3(FM3/FO2.5) 20.5±0.13b 
1
76.0±0.30c  271.3±1.54 2.08±0.01 51.6±0.89 1.07±0.02 
D4(FM3/FO2.5/BUT) 20.9±0.21b 
1
77.2±1.72bc  269.3±8.35 2.07±0.03 56.8±4.42 1.01±0.05 
        
Week 31 (August-December) 
D1(FM23/FO15) 
Q
87.6±0.87a 318.3±0.16a  263.2±4.71a 1.02±0.01 213.1±6.96 1.08±0.03 
D2(FM3/FO6) 
1
82.7±0.04ab 321.6±1.17a  298.2±3.98b 1.10±0.07 225.9±0.3 1.06±0.01 
D3(FM3/FO2.5) 
1
76.0±0.30c 298.1±4.64b  302.7±2.22b 1.10±0.01 213.1±2.87 1.05±0.01 
D4(FM3/FO2.5/BUT) 
1
77.2±1.72bc 296.7±4.62b  291.7±1.97b 1.08±0.01 215.1±0.80 1.03±0.01 
        
Overall (May-December)      
D1(FM23/FO15) 
Q
15.0±0.04 318.3±0.16a  2027±1.08a 1.42±0.01 298.2±8.46 1.01±0.03 
D2(FM3/FO6) 
1
15.3±0.05 321.6±1.17a  2004±7.6a 1.41±0.01 307.7±0.47 0.99±0.01 
D3(FM3/FO2.5) 
1
15.2±0.03 298.1±4.64b  1856±30.5b 1.37±0.01 292.7±2.60 0.96±0.01 
D4(FM3/FO2.5/BUT) 
1
15.4±0.04 296.7±4.62b  1828±30.1b 1.37±0.01 296.1±1.2 0.95±0.01 
Table 3. Organosomatic indexes and whole body composition of juvenile gilthead sea bream sampled in August (week 13) and December (week 31).  
Biometric data are the mean  SEM of 12 fish (4 per each dietary triplicate). Data on whole body composition are the mean of 4 pooled fish per each 
dietary triplicate. 
1
Viscerosomatix index = (100 x viscera weight)/fish weight 
2
Mesenteric index = (100 x mesenteric fat weight)/fish weight 
3
Hepatosomatic index = (100 x liver weight)/fish weight 
  
 August 2013  December 2013  Two-way ANOVA (P-values) 
 D1 D2 D3 D4 
 
D1 D2 D3 D4 
 
Diet Time 
Diet x Time 
Interaction 
Viscera (g) 8.52±0.19 7.26±0.24 7.80±0.28 7.46±0.29  22.6±0.85 21.63±0.88 21.41±1.01 20.8±0.65  0.064 <0.001 0.785 
Mesenteric fat (g) 1.64±0.14 1.40±0.13 1.35±0.09 1.47±0.17  4.54±0.51 4.28±0.52 3.44±0.44 3.64±0.37  0.113 <0.001 0.371 
Liver (g) 1.49±0.04 1.25±0.04 1.35±0.04 1.30±0.04  6.42±0.90 7.07±0.26 7.24±0.47 6.68±0.33  0.414 <0.001 0.148 
Intestine length (cm) 11.7±0.60 11.4±0.60 11.8±0.70 11.2±0.70  13.3±0.51 13.33±0.60 14.20±0.71 13.04±0.46  0.545 <0.001 0.950 
VSI (%)
1 9.04±0.15 8.40±0.20 9.40±0.26 8.81±0.22  6.67±0.37 6.38±0.19 6.47±0.18 6.26±0.18  0.099 <0.001 0.318 
MSI (%)
2 1.79±0.13 1.61±0.13 1.67±0.11 1.72±0.19 
 
1.34±0.15 1.35±0.13 1.03±0.12 0.99±0.15  0.526 <0.001 0.505 
HSI (%)
3 1.56±0.07 1.47±0.07 1.63±0.07 1.51±0.07 
 
1.87±0.27 2.09±0.07 2.29±0.07 2.07±0.09  0.051 <0.001 0.069 
 
        
     
Whole body composition  
(% wet weight) 
    
 
    
 
   
Moisture 66.7±0.27 66.8±0.72 67.8±0.02 66.3±0.26  64.08±0.34 62.80±0.58 62.85±0.72 64.13±0.34  0.342 <0.001 0.133 
Crude protein 16.1±0.49 16.2±0.39 15.9±0.17 16.3±0.03  18.06±0.05 18.58±0.82 18.01±0.55 17.72±1.56  0.928 <0.001 0.738 
Crude lipid 8.98±0.09 9.09±0.40 8.96±0.34 9.38±0.13  12.60±0.73 12.65±1.31 12.07±0.02 11.63±0.01  0.932 0.004 0.917 
Table 4. Haematology and blood biochemistry of juvenile gilthead sea bream sampled in August (week 13) and December (week 31).  
Data are the mean  SEM of 10-12 fish. Different superscript letters indicate significant differences within a sampling time (SNK test, P<0.05). 
  
 August 2013 
 
December 2013     Two-way ANOVA (P-values) 
 D1 D2 D3 D4 
 
D1 D2 D3 D4 






















































  0.007 <0.001 <0.001 
Glucose (mg/dl) 46.8±1.61 53.5±5.12 53.7±2.28 48.9±2.12 
 
46.1±1.95 48.9±2.2 49.1±1.73 47.4±3.41  0.294 0.080 0.621 
Triglycerides (mM) 0.56±0.03 0.47±0.04 0.65±0.07 0.63±0.05 
 
4.97±2.80 0.891±0.09 0.951±0.09 3.58±0.94  0.309 0.033 0.323 


















  <0.001 <0.001 0.040 


















  <0.001 <0.001 <0.001 
VLDL/LDL cholesterol 
(mg/dl) 












<0.001 <0.001 <0.001 
Total proteins (g/l) 40.9±1.39 41.5±1.67 40.8±1.89 42.2±1.36 
 
49.2±1.26 50.78±1.49 47.18±0.88 50.7±0.96  0.306 <0.001 0.782 
ALAT (U/l) 1.34±0.14 1.18±0.27 1.30±0.19 1.28±0.21 
 
1.68±0.20 1.68±0.42 1.48±0.21 1.29±0.20  0.777 0.101 0.886 
ASAT (U/l)  16.1±3.62 18.7±3.68 19.7±4.19 17.9±3.7 
 
13.5±2.15 16.9±3.13 11.02±0.99 10.4±2.18  0.661 0.025 0.217 
GLDH (U/l) 0.68±0.24 0.94±0.20 0.49±0.08 0.57±0.15 
 
0.74±0.20 0.53±0.12 0.85±0.32 0.72±0.10  0.505 0.734 0.932 
ALP (U/l) 96.5±3.61 101.9±5.41 97.7±7.01 99.0±4.85 
 
81.9±4.34 89.8±7.01 78.4±5.34 92.6±7.45  0.316 0.008 0.213 
Creatinine (mg/dl) 0.11±0.02 0.1276±0.01 0.125±0.02 0.120±0.03 
 











7.05±0.62 7.75±0.54 7.12±0.39 6.77±0.69  0.050 <0.001 0.012 










  0.010 0.383 <0.001 
Chloride (mg/dl) 461.3±13.6 468.3±6.7 473.8±9.3 442.8±7.2 
 
429.9±10.8 448.8±10.7 459.4±11.3 429.7±15.3  0.065 0.050 0.915 
Magnesium (mg/ml) 1.92±0.07 2.07±0.08 1.89±0.08 1.98±0.07 
 
1.76±0.05 1.83±0.03 1.72±0.04 1.96±0.0.08  0.197 0.004 0.016 
Phosphate (mg/dl) 11.3±1.27 11.9±1.55 12.1±1.60 12.1±1.59 
 
11.2±0.25 10.1±0.31 10.40±0.31 10.98±0.12  0.997 0.517 0.966 
Antioxidant capacity 
(Trolox mM) 
0.92±0.03 0.91±0.03 0.84±0.03 0.72±0.08 
 
1.12±0.04 1.14±0.03 1.104±0.02 1.14±0.04 
 
0.153 <0.001 0.097 
Lysozyme (U/l) 190.5±32.9 208.8±117.4 118.8±30.1 125.7±46.6 
 
56.5±12.7 85.7±28.9 51.8±18.1 32.5±19.1  0.622 <0.001 0.361 
Respiratory burst (IRLU) 388.1±40.8 539.9±51.4 758.6±247.1 485.1±52.2 
 
3093.6±743.9 4882.9±671.7 5170.4±1235.5 2926.8±672.3  0.131 <0.001 0.336 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A GHR-I IGFALS MSTN PAX7 CTSD UBE2A Hsp30 IL-1β IL-10 SIRT4 SCO1 PPC1 
B GHR-II INSR MEF2A SOX3 CTSL UBE2D2 mtHsp60 IL-1R1 IL-10RA SIRT5 UCP1 PPC2 
C IGF-I IGFR1 MEF2C MET CTSS UBE2L3 mtHsp70 IL-1R2 IL-10RB PGC1α UCP2 PPC3 
D IGF-II IGFR2 FST CAPN1 PSMD4 UBE2N Hsp90α IL-6 TNF-α CPT1A UCP3 PPC4 
E IGFBP1 MyoD1 CAV3 CAPN2 PSD12 CUL2 Hsp90β IL-6RA TRADD CS LXRα NPC 
F IGFBP2 MyoD2 DES CAPN3 PSMA5 CUL3 GRP-170 IL-6RB SIRT1 ND2 PPARα NPC 
G IGFBP4 Myf5 CDH15 CAST PSMB1 CUL5 GRP-94 IL-8 SIRT2 NDUFAF2 PPARγ ACTB 
H IGFBP7 Myf6 PCNA CTSB UCHL3 mtHsp10 DER-1 IL-8RA SIRT3 COXI  ACTB 
Position Symbol Description Accession No. 
A1 GHR-I Growth hormone receptor I AF438176 
B1 GHR-II Growth hormone receptor II AY573601 
C1 IGF-I Insulin-like growth factor-I EF563837 
D1 IGF-II Insulin-like growth factor-II EF563836 
E1 IGFBP1 Insulin-like growth factor binding protein 1 KM522771 
F1 IGFBP2 Insulin-like growth factor binding protein 2 AF377998 
G1 IGFBP4 Insulin-like growth factor binding protein 4 KM658998 
H1 IGFBP7 Insulin-like growth factor binding protein 7 KM522772 
A2 IGFALS Insulin-like growth factor-binding protein complex acid 
labile subunit 
KM522773 
B2 INSR Insulin receptor KM522774 
C2 IGFR1 Insulin-like growth factor receptor I KM522775 
D2 IGFR2 Cation-independent mannose-6-phosphate receptor KM522776 
E2 MyoD1 Myoblast determination protein 1 AF478568 
F2 MyoD2 Myoblast determination protein 2 AF478569 
G2 Myf5 Myogenic factor 5 JN034420 
H2 Myf6 Myogenic factor 6 JN034421 
A3 MSTN Growth/ differentiation factor 8 (Myostatin) AF258448 
B3 MEF2A Myocyte-specific enhancer factor 2A KM522777 
C3 MEF2C Myocyte-specific enhancer factor 2C KM522778 
D3 FST Follistatin AY544167 
E3 CAV3 Caveolin 3 KM522779 
F3 DES Desmin KM522780 
G3 CDH15 Cadherin 15 KM522781 
H3 PCNA Proliferating cell nuclear antigen  KF857335 
A4 PAX7 Paired box 7 KM522782 
B4 SOX3 Transcription factor SOX3  KM522783 
C4 MET c-met/hepatocyte growth factor receptor KM522784 
D4 CAPN1 Calpain 1 KF444899 
E4 CAPN2 Calpain 2 KF444900 
F4 CAPN3 Calpain 3 KM522785 
G4 CAST Calpastatin KM522786 
H4 CTSB Cathepsin B KJ524457 
  
Table S1. Continued. 
 
Position Symbol Description Accession No. 
A5 CTSD Cathepsin D AF036319 
B5 CTSL Cathepsin L KM522787 
C5 CTSS Cathepsin S KM522788 
D5 PSMD4 26S proteasome non-ATPase regulatory subunit 4 KM522789 
E5 PSD12 26S proteasome non-ATPase regulatory subunit 12 KM522790 
F5 PSMA5 Proteasome subunit alpha type-5 KM522791 
G5 PSMB1 Proteasome subunit beta type-1 KM522792 
H5 UCHL3 Ubiquitin carboxyl-terminal hydrolase isozyme L3 KM522793 
A6 UBE2A Ubiquitin-conjugating enzyme E2 A KM522794 
B6 UBE2D2 Ubiquitin-conjugating enzyme E2 D2 KM522795 
C6 UBE2L3 Ubiquitin-conjugating enzyme E2 L3 KM522796 
D6 UBE2N Ubiquitin-conjugating enzyme E2N KM522797 
E6 CUL2 Cullin 2 KM522798 
F6 CUL3 Cullin 3 KM522799 
G6 CUL5 Cullin 5 KM522800 
H6 mtHsp10 10 kDa heat shock protein, mitochondrial JX975224 
A7 Hsp30 30 kDa heat shock protein KM522801 
B7 mtHsp60 60 kDa heat shock protein, mitochondrial JX975227 
C7 mtHsp70 70 kDa heat shock protein, mitochondrial DQ524993 
D7 Hsp90α 90 kDa heat shock protein alpha 1 KM522802 
E7 Hsp90β 90 kDa heat shock protein beta KM522803 
F7 GRP-170 Glucose-regulated protein, 170 kDa JQ308821 
G7 GRP-94 Glucose-regulated protein, 94 kDa JQ308820 
H7 DER-1 Derlin-1 JQ308825 
A8 IL-1β Interleukin-1 beta AJ419178 
B8 IL-1R1 Interleukin-1 beta receptor 1 JX976615 
C8 IL-1R2 Interleukin-1 beta receptor 2 AM296027 
D8 IL-6 Interleukin-6 EU244588 
E8 IL-6RA Interleukin-6 receptor A JX976616 
F8 IL-6RB Interleukin-6 receptor B JX976617 
G8 IL-8 Interleukin-8 JX976619 
H8 IL-8RA Interleukin-8 receptor A JX976620 
A9 IL-10 Interleukin-10 JX976621 
B9 IL-10RA Interleukin-10 receptor A JX976622 
C9 IL-10RB Interleukin-10 receptor B JX976623 
D9 TNF-α Tumor necrosis factor-alpha AJ413189 
E9 TRADD Tumor necrosis factor receptor type 1-associated DEATH 
domain protein 
KM522804 
F9 SIRT1 Sirtuin 1 KF018666 
G9 SIRT2 Sirtuin 2 KF018667 
H9 SIRT3 Sirtuin 3 KF018668 
A10 SIRT4 Sirtuin 4 KF018669 
B10 SIRT5 Sirtuin 5 KF018670 
C10 PGC1α Proliferator-activated receptor gamma coactivator 1 alpha JX975264 
  
Table S1. Continued. 
GH/IGF system: GHR-I, GHR-II, IGF-I, IGF-II, IGFBP1, IGFBP2, IGFBP4, IGFBP7, IGFALS, INSR, IGFR1, 
IGFR2 
Muscle growth and differentiation: MyoD1, MyoD2, Myf5, Myf6, MSTN, MEF2A, MEF2C, FST, CAV3, DES, 
CDH15, PCNA, PAX7, SOX3, MET 
Protein breakdown: CAPN1, CAPN2, CAPN3, CAST, CTSB, CTSD, CTSL, CTSS, PSMD4, PSD12, PSMA5, 
PSMB1, UCHL3, UBE2A, UBE2D2, UBE2L3, UBE2N, CUL2, CUL3, CUL5 
Protein folding and assembly: mtHsp10, Hsp30, mtHsp60, mtHsp70, Hsp90α, Hsp90β, GRP-170, GRP-94, DER-1 
Inflammatory/anti-inflammatory response : IL-1β, IL-1R1, IL-1R2, IL-6, IL-6RA,IL-6RB, IL-8, IL-8RA, IL-10,  IL-
10RA, IL-10RB, TNF-α, TRADD 
Energy sensing: SIRT1, SIRT2, SIRT3, SIRT4, SIRT5 
Oxidative phosphorylation: PGC1α, CPT1A, CS, ND2, NDUFAF2, COXI, SCO1 
Mitochondrial respiration uncoupling: UCP1, UCP2, UCP3 
Transcription-related factors of lipid metabolism: LXRα, PPARα, PPARγ 
Position Symbol Description Accession No. 
D10 CPT1A Carnitine palmitoyltransferase 1A JQ308822 
E10 CS Citrate synthase JX975229 
F10 ND2 NADH-ubiquinone oxidoreductase chain 2 KC217559 
G10 NDUFAF2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 2 
KC217598 
H10 COXI Cytochrome c oxidase subunit I KC217652 
A11 SCO1 SCO1 protein homolog, mitochondrial KC217649 
B11 UCP1 Uncoupling protein 1 FJ710211 
C11 UCP2 Uncoupling protein 2 JQ859959 
D11 UCP3 Uncoupling protein 3 EU555336 
E11 LXRα Liver X receptor α FJ502320 
F11 PPARα Peroxisome proliferator-activated receptor α AY590299 
G11 PPARγ Peroxisome proliferator-activated receptor γ AY590304 
A12-D2 PPC Positive PCR control (serial dilutions of standard gene) AY590304 
E12-F12 NPC Negative PCR control   
G12-H12 ACTB β-actin X89920 
Table S2. Characteristics of new assembled sequences according to BLAST searches. 
 
a
Gene identity determined through BLAST searches: IGFBP1, Insulin-like growth factor binding protein 
1; IGFBP7, Insulin-like growth factor binding protein 7; IGFALS, Insulin-like growth factor-binding 
protein complex acid labile subunit; INSR, Insulin receptor; IGF1R, Insulin-like growth factor receptor I; 
IGF2R, Insulin-like growth factor receptor II; MEF2A, Myocyte-specific enhancer factor 2A; MEF2C, 
Myocyte-specific enhancer 2C; CAV3, Caveolin 3; DES, Desmin; CDH15, Cadherin-15; PAX7, Paired 
box protein 7; SOX3, Transcription factor SOX3; MET, c-met/hepatocyte growth factor receptor; 
CAPN3, Calpain 3; CAST, Calpastatin; CTSL, Cathepsin L; CTSS, Cathepsin S; PSMD4, 26S 
proteasome non-ATPase regulatory subunit 4; PSMD12, 26S proteasome non-ATPase regulatory subunit 
12; PSMA5, Proteasome subunit alpha type-5; PSMB1A, Proteasome subunit beta type 1-A; UCHL3, 
Ubiquitin carboxyl-terminal hydrolase isozyme L3; UBE2A, Ubiquitin-conjugating enzyme E2 A;  
UBE2D2, Ubiquitin-conjugating enzyme E2 D2; UBE2L3, Ubiquitin-conjugating enzyme E2 L3; 
UBE2N, Ubiquitin-conjugating enzyme E2 N; CUL2, Cullin 2; CUL3, Cullin 3; Hsp30, 30kDa heat 
shock protein; Hsp90α, 90kDa heat shock protein alpha 1; Hsp90β, 90kDa heat shock protein beta; 
TRADD, Tumor necrosis factor receptor type 1-associated DEATH domain protein. 
b
















C2_29775 1283 IGFBP1 AEI25510 6e-38 <1-221 
C2_31065 912 IGFBP7 XP_008302045 2e-133 <1-732 
C2_8119 2720 IGFALS XP_008295360 0.0 55-1788 
C2_27455 1259 INSR CAA12279 0.0 <2->1259 
C2_94457 462 IGFR1 XP_008281734 9e-8 <1->462 
C2_6981 2246 IGFR2 XP_008279839 0.0 96->2246 
C2_29713 1018 MEF2A XP_006628936 4e-54 362->634 
C2_20859 861 MEF2C XP_008283713 1e-173 <3->861 
C2_894 1619 CAV3 XP_008295093 2e-98 183-638 
C2_3681 2168 DES XP_008279286 0.0 94-1527 
C2_26597 1082 CDH15 XP_008291154 0.0 <1->1082 
C3_c43349 509 PAX7 XP_007552599 4e-44 <1-339 
C3_c8164 1162 SOX3 AFV74658 0.0 226-1122 
C2_25143 423 MET XP_008276200 1e-64 <1->423 
C2_2905 1863 CAPN3 ACY78226 0.0 244->1863 
C2_12340 258 CAST XP_008318906 8e-30 <1->258 
C2_302 1560 CTSL ADJ21807 0.0 76-1086 
C2_386 1227 CTSS BAK55650 0.0 51-1064 
C2_3430 1469 PSMD4 XP_005472747 0.0 40-1167 
C2_1392 2208 PSMD12 XP_008274826 0.0 117-1487 
C2_89 1171 PSMA5 ACQ58745 3e-175 126-851 
C2_45131 245 PSMB1 XP_008284963 1e-49 <2->245 
C2_660 1389 UCHL3 XP_003451662 4e-141 120-818 
C2_659 1293 UBE2A XP_003452937 1e-103 147-605 
C2_5227 1243 UBE2D2 XP_003451814 0.0 260-703 
C2_6947 1839 UBE2L3 XP_003976109 3e-87 16-480 
C2_17030 926 UBE2N XP_003972864 4e-102 171-632 
C2_4824 3012 CUL2 CBN81753 0.0 117-2351 
C2_4406 2400 CUL3 XP008279409 0.0 <1-1902 
C2_13502 1347 CUL5 XP_008331257 0.0 <1-1347 
C2_77908 448 Hsp30 XP_008422086 3e-60 1->448 
C2_4132 2694 Hsp90α XP_008297037 0.0 160-2337 
C2_42 2781 Hsp90β AAQ95586 0.0 135-2324 
C2_2326 1432 TRADD XP_008302445 3e-174 65-946 
Table S3. Forward and reverse primers for real-time PCR.  
 
Gene name Symbol  Primer sequence 
Growth hormone receptor I GHR-I F ACC TGT CAG CCA CCA CAT GA 
  R TCG TGC AGA TCT GGG TCG TA 
    
Growth hormone receptor II GHR-II F GAG TGA ACC CGG CCT GAC AG 
  R GCG GTG GTA TCT GAT TCA TGG T 
    
Insulin-like growth factor-I IGF-I F TGT CTA GCG CTC TTT CCT TTC A 
  R AGA GGG TG TGG CTA CAG GAG ATA C 
    
Insulin-like growth factor-II IGF-II F TGG GAT CGT AGA GGA GTG TTG T 
  R CTG TAG AGA GGT GGC CGA CA 
    
Insulin-like growth factor 
binding protein 1 
IGFBP1 F ACA AAC CAA AAC AGT GCG AGT CCT C 
 R CCG TTC CAA GAG TTC ACA CAC CAG 
    
Insulin-like growth factor 
binding protein 2 
IGFBP2 F AGC GAT GTG TCC TGA GAT AGT GAG 
 R GCA CCG TGG CGT GTA GAC C 
    
Insulin-like growth factor 
binding protein 4 
IGFBP4 F GGC ATC AAA CAC CCG CAC AC 
 R ATC CAC GCA CCA GCA CTT CC 
    
Insulin-like growth factor 
binding protein 7 
IGFBP7 F GCC ACA GCT CCG ATC ATC GTC ACT 
 R AGC CAC TCA CAT TGT AGA CCT CAC CTG 
    
Insulin-like  growth factor 
binding protein complex 
acid labile subunit 
IGFALS F GCT CGG AAC TTC ACT CAA GTC CCA TC 
 R AGT TGC CAT CCA GCC AGA TAG AAT GA 
   
Insulin receptor INSR F ACG GAC AGC AAG AAG GCA GAG AAT C 
  R GGC TTC AAC GGT CGG ATC AGG T 
    
Insulin-like growth factor 
receptor I  
IGFR1 F TCA ACG ACA AGT ACG ACT ACC GCT GCT 
 R CAC ACT TTC TGG CAC TGG TTG GAG GTC 




IGFR2 F ACA TTC GGG CAG CAC TCC TAA GAT 
 R CCA GTT CAC CTC GTA GCG ACA GTT 
   
Myoblast determination 
protein 1 
MyoD1 F ATG GAG CTG TCG GAT ATC TCT TTC 
 R GAA GCA GGG GTC ATC GTA GAA ATC 
    
Myoblast determination 
protein 2 
MyoD2 F CCA ACT GCT CTG ATG GCA TGA TGG ATT TC 
 R GAC CGT TTG CTT CTC CTG GAC TCG TAT G 
    
Myogenic factor 5 Myf5 F GCA TGG TTG ACA GCA ACA GTC CAG TGT 
  R TGT CTT ATC GCC CAA AGT GTC GTT CTT CAT 
    
Myogenic factor 6 Myf6/MRF
4/herculin 
F GCA GCA ATG ACA AAC CAG AGA GAC GGA ACA 
 R GAG GCT GGA GGA CGC CGA AGA TTC A 
    
Growth/ differentiation MSTN/GD F AAG AGC AGA TCA TCT ACG GCA AGA TCC 
R TCA AGA GCA TCC ACA ACG GTC TAC CA 
factor 8 F-8 
    
Myocyte-specific enhancer 
factor 2A 
MEF2A F ATG GAC GAG AGG AAC AGG CAG GTT A 
 R GGC TAT CTC ACA GTC ACA TAG TAC GCT CAG 
    
Myocyte-specific enhancer 
factor 2C 
MEF2C F TAG CAA CTC CCA CTC TAC CAG GAC AAG 
 R GGA ATA CTC GGC ACC ATA AGA AGT CG 
    
Follistatin FST F GGA CCA GAC AAA CAA CGC ATA TTG 
  R CAT AGA TGA TCC CGT CGT TTC CAC 
    
Caveolin 3 CAV3 F CAC CAC CTT CAC TGT GTC CAA 
  R CGA CGG GGA TGC CAA AGA C 
    
Desmin DES F ATT CAC CAG AAG GAG GAG GCT GAG AAC AAC 
  R GAG TGG CAT TGT CAA CAT CGG CTC TGA 
    
Cadherin-15 CDH15 F AAC GCT TAT CTG AGC TAC TCT ATC ATT GG 
  R CTG GTT GTT GAT ACC GAA CAT TGT 
    
Proliferating cell nuclear 
antigen 
PCNA F CGT ATC TGC CGT GAC CTG T 
 R AGA ACT TGA CTC CGT CCT TGG 
    
Paired box protein 7 PAX7 F GAA CGT GAG CTT GTC CAC CCA GAG G 
  R GCC GAG TGG TCT CCC AGT TTC ATC C 
    
Trascription factor SOX3 SOX3 F ACA TGA AGG AGC ACC CGG ATT ATA AAT ACC 
  R GGG CAA AGA ATA CTT GTC TTT CTT GAG CAA 
    
Hepatocyte growth factor 
receptor 
MET F GCC ACA GGA AAC AAG ATT ACT AAA GTC CCT 
 R AGC AAA CAG GAA GTA CAG GTG GTA AGC 
    
Calpain 1 CAPN1 F CAG AAC CAC AAC GCC GTG AAG TTT 
  R AGG CAC TGG GCT TTA AGA CTC TCG 
    
Calpain 2 CAPN2 F CAT CTA TAA GAA GAA CGA CTC GGA CAA CTC 
  R TGT TGA GGC TGA AAC CTG CGT CTT TA  
    
Calpain 3 CAPN3 F TAC GAA GAG GAT GAC GAC CCA GAG 
 
 R GCA TCA GAG CCA CAA CGA GAG T 
    
Calpastatin CAST F CCC AAA CCC GAG CCC ACC AT 
  R GAC AAG AAG TCC AGA GCG TCT CCA GTA 
    
Cathepsin B CTSB F TGA TTC CCA TGT CGG TTG TC 
 
 R GGG TCT ACT GCC ATT CAC AT 
    
Cathepsin D CTSD F CAC ACT GGG AGA CCT GCA CTA TGT CAA TG 
 
 R ATT GCC AAC TTG AAG TCC GTC CAT ACC 
    
Cathepsin L CTSL F GGG AAC GGA TGA CCA GCC TTG T 
 
 R CGG TGT CAT TGG CAG AGT TGT AGT TG 
    
Cathepsin S CTSS F CCA CAT GGG AGA CCT GAC ACC AGA GGA GAT 
 
 R TCA GTG GGA GGA ATG AAT GTG GCG AAA GAC 
    
26S proteasome non-
ATPase regulatory subunit 4 
PSMD4 F CAT CCA CAC CTG CTC TAC CAG ACT TCA 
 R CGT AGG CGA TCT GTT CAT CCT CTG TCA T 
    
26S proteasome non-
ATPase regulatory subunit 
12 
PSMD12 F CCT GCC ACA GAT GTC TTC TCT TAT TCA 
 R GCC ATT ATT CTG ATG TTA TGC TCC ACC A 
   
Proteasome subunit alpha 
type-5 
PSMA5 F TGA CAA GAT CGG AGT ATG ACA GAG GTG TGA 
 R CCT CGA TGG CAT ATT CAA CCT GGA ACA ATC 
    
Proteasome subunit beta 
type-1 
PSMB1 F TGG ATG AAG AGG GCA AAG GAG CAG TGT A 
 R TTG TAT GTG TCT CTC TGG TAG GAG CCC ACT 
    
Ubiquitin carboxyl-terminal 
hydrolase isozyme L3 
UCHL3 F CAG TGA CAG AGA AGT ATG AGA CAT TCA A 
 R CGT TTC CAA TAG TTT GCT TAA TGA AGT AGA 
    
Ubiquitin-conjugating 
enzyme E2 A 
UBE2A F CAT CAT GGT GTG GAA TGC AGT CAT ATT TGG 
 R GGG TTT GTT GGG GTA TTC TTC TGT GAA CT 
    
Ubiquitin-conjugating 
enzyme E2 D2 
UBE2D2 F TCT GCT GTG CGA CCC AAA CC 
 R GAT GCG GGC GAT CTC GGG TA 
    
Ubiquitin-conjugating 
enzyme E2 L3 
UBE2L3 F CCT CAT TGC ATT GGT GAA CG 
 R TTG AGT ATT CTT CTG CTA GGT CAG 
    
Ubiquitin-conjugating 
enzyme E2 N 
UBE2N F TTG CCT CGT AGG ATT ATT AAG GAG AC 
 R CCT GAA ATG ACC ACA TGG AAG TAA CG 
    
Cullin 2 CUL2 F GGC ATC CGA GGC ACC AGT AAC C 
  R TGA ACC TCC AGC ACT GAC TCC ACA A 
    
Cullin 3 CUL3 F AAA GGA GGA TGG TTC AGA AGT TGG 
  R CAG TAT GTG CTT ACG GGT GTT AGA G 
    
Cullin 5 CUL 5 F CAA ACT CAA GAG GCA GGT GTT GTC GTA 
  R GTA GAA TAG TGT TCC CTC TGC GAA GTC T 
    
10 kDa heat shock protein, 
mitochondria 
mtHsp10 F CAT GCT GCC AGA GAA GTC TCA AGG 
 R AGG TCC CAC TGC CAC TAC TGT 
    
30kDa heat shock protein  Hsp30 F ATC TCT CAA CAA GAC CAC ACA ACA CT 
  R TAC AGG CCA GTA CAA GTC CAT GAA TG 
    
60 kDa heat shock protein, 
mitochondrial 
mtHsp60 F TGT GGC TGA GGA TGT GGA TGG AGA G 
 R GCC TGT TGA GAA CCA AGG TGC TGA G 
    




F TCC GGT GTG GAT CTG ACC AAA GAC 
R TGT TTA GGC CCA GAA GCA TCC ATG 
    
90kDa heat shock protein 
alpha 1 
Hsp90a F CTC ACA GTT CAT CGG CTA CCC TAT CA 
 R AAC TTC CTC TTC CTT CTC TCC CTC ATC AAG 
    
90kDa heat shock protein 
beta 
Hsp90b F AGA ATA ACA TCA AGC TGT ACG TCA GGA GAG 
 R CAC CAC ACC ACG GAC AAA GTT CAG ATA CTC 
    
Glucose-regulated protein, 
170 kDa 
GRP-170 F CAG AGG AGG CAG ACA GCA AGA C 
 R TTC TCA GAC TCA GCA TTT CCA GAT TTC 
    
Glucose-regulated protein, 
94 kDa 
GRP-94 F AAG GCA CAG GCT TAC CAG ACA G 
 R CTT CAG CAT CAT CGC CGA CTT TC 
    
Derlin-1 DER-1 F ACT GCC TCG GTT GCC TTT CC 
  R TGG CTG TCA CAA GTC TCC AGA TAT G 
    
Interleukin-1 beta IL-1β F GCG ACC TAC CTG CCA CCT ACA CC 
  R TCG TCC ACC GCC TCC AGA TGC 
    
Interleukin-1 beta receptor 1 IL-1R1 F GAA GCT GTA CGA CGC CTA C 
  R CTC CAC TGC CTT ACT GTA TCC 
    
Interleukin-1 beta receptor 2 IL-1R2 F CCT GAC CTC TCC GTG ACC TCT AA 
  R TGG CTG CTG CTG CTG ATG A 
    
Interleukin-6 IL-6 F TCT TGA AGG TGG TGC TGG AAG TG 
  R TCT TGA AGG TGG TGC TGG AAG TG 
    
Interleukin-6 receptor A IL-6RA F GCA GTG CTC GTA CTC TTC 
  R CTC CGC TCT TCC TCA TTG 
    
Interleukin-6 receptor B IL-6RB F CAG TGT CGG AGT ATG TGG TTG AGT 
  R CCC TCT GCC AGT CTG TCC AA 
    
Interleukin-8 IL-8 F CAG CAG AGT CTT CAT CGT CAC TAT TG 
  R AGG CTC GCT TCA CTG ATG G 
    
Interleukin-8 receptor A IL-8RA F CTT GTT TCA TCT GAC GAT AG 
  R AAG AGG ATG CTT GTG TAG 
    
Interleukin-10 IL-10 F AAC ATC CTG GGC TTC TAT CTG 
  R GTG TCC TCC GTC TCA TCT G 
    
Interleukin-10 receptor A IL-10RA F GAG GAC AAT GAA GAG GAA GAC AGG AG 
  R TGT TCG TAG CGG AGT TGG ACT 
    
Interleukin-10 receptor B IL-10RB F AGA CCC ACA GGC TTC AGA T 
  R GCA GCG TCA CCA GGT TAG 
    
Tumor necrosis factor -
alpha 
TNF-α F CAG GCG TCG TTC AGA GTC TC 
 R CTG TGG CTG AGA GCT GTG AG 
    
Tumor necrosis factor TRADD F GAG GGA AAG TTC ATC GTG TTC AAA GTC ATC 
receptor type 1-associated 
DEATH domain protein 
 R AAC GGA TCA GCA TCA TGG ACC TTA AGT A 
   
Sirtuin1 SIRT1 F GGT TCC TAC AGT TTC ATC CAG CAG CAC ATC 
  R CCT CAG AAT GGT CCT CGG ATC GGT CTC 
    
Sirtuin2 SIRT2 F GAA CAA TCC GAC GAC AGC AGT GAA G 
  R AGG TTA CGC AGG AAG TCC ATC TCT 
    
Sirtuin3 SIRT3 F CTG CCA AGT CCT CAT CCC 
  R CTT CAC CAG ACG AGC CAC 
    
Sirtuin4 SIRT4 F GGC TGG CGG AGT CGG ATG 
  R TCC TGA ATA CAC CTG TGA CGA AGA C 
    
Sirtuin5 SIRT5 F CAG ACA TCC TAA CCC GAG CAG AG 
  R CCA CGA GGC AGA GGT CAC A 
    
Proliferator-activated 
receptor gamma coactivator 
1 alpha 
PGC1α F CGT GGG ACA GGT GTA ACC AGG ACT C 
 R ACC AAC CAA GGC AGC ACA CTC TAA TTC T 
   
Carnitine 
palmitoyltransferase 1A 
CPT1A F GTG CCT TCG TTC GTT CCA TGA TC 
 R TGA TGC TTA TCT GCT GCC TGT TTG 
    
Cytrate synthase CS F TCC AGG AGG TGA CGA GCC 
  R GTG ACC AGC AGC CAG AAG AG 
    
NADH-ubiquinone 
oxidoreductase chain 2 
ND2 F TAG GTT GAA TGA CCA TCG TA 
 R GGC TAA GGA GTT GAG GTT 
    
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, assembly 
factor 2 
NDUFAF2 F AGG CAG CAT ACC GAT AGA G 
 R ACT CAT TCT TCA GCA ACT CCT 
   
   
Cytochrome c oxidase 
subunit I 
COXI F GTC CTA CTT CTT CTG TCC CTT CCT GTT CT 
 R AGG TTT CGG TCT GTA AGG AGC ATT GTA ATC 
    
SCO1 protein homolog, 
mitochondrial 
SCO1 F ACA ACA ACA AGC CCA CCA AGA 
 R GAC AGT GAG TGA ACC CGA AGT AGA T 
    
Uncoupling protein 1 UCP1 F GCA CAC TAC CCA ACA TCA CAA G 
  R CGC CGA ACG CAG AAA CAA AG 
    
Uncoupling protein 2 UCP2 F CGG CGG CGT CCT CAG TTG 
  R AAG CAA GTG GTC CCT CTT TGG TCA T 
    
Uncoupling protein 3 UCP3 F AGG TGC GAC TGG CTG ACG 
  R TTC GGC ATA CAA CCT CTC CAA AG 
    
Liver X receptor α LXRα F GCA CTT CGC CTC CAG GAC AAG 
  R CAG TCT TCA CAC AGC CAC ATC AGG 
    
Peroxisome proliferator- PPARα F TCT CTT CAG CCC ACC ATC CC 
activated receptor α  R ATC CCA GCG TGT CGT CTC C 
    
Peroxisomeproliferator-
activated receptor γ 
PPARγ F CGC CGT GGA CCT GTC AGA GC 
 R GGA ATG GAT GGA GGA GGA GGA GAT GG 
    
 
  
Table S4. Relative gene expression of growth-related genes in the liver of gilthead sea bream sampled in 
August 2013 (week 13). Data are the mean ± SEM of 6-7 fish. All data are referenced to the expression 
level of IGFR2 of control fish (D1 diet) with an arbitrarily assigned value of 1. Different superscript letters 
in each row indicate significant differences among dietary treatments (SNK test, P<0.05). 
 D1 D2 D3 D4 P-value 
GHR-I 19.41±0.99 18.53±2.07 19.63±2.12 20.12±3.42 0.898 










IGF-II 28.09±5.30 30.36±2.76 20.83±4.96 23.21±2.85 0.335 
IGFBP1 0.11±0.03 0.11±0.01 0.14±0.01 0.10±0.01 0.212 










IGFBP7 6.44±0.71 5.15±0.48 4.57±0.73 4.31±0.53 0.069 
IGFALS 176.7±42.1 129.1±10.2 101.8±12.1 126.7±14.3 0.214 
INSR 3.05±0.11 2.25±0.26 2.68±0.25 2.56±0.14 0.101 
IGFR1 0.25±0.02 0.19±0.01 0.24±0.01 0.21±0.01 0.057 
IGFR2 1.04±0.06 0.90±0.06 0.95±0.05 0.96±0.07 0.469 
MEF2A 2.94±0.26 2.32±0.12 2.50±0.25 2.23±0.15 0.083 










MET 4.11±0.59 3.81±0.21 3.82±0.59 3.47±0.31 0.785 
CAPN1 2.94±0.26 2.27±0.25 3.16±0.33 2.24±0.23 0.051 
CAPN2 1.24±0.17 1.04±0.04 1.37±0.10 1.18±0.08 0.212 
CAPN3 0.09±0.02 0.08±0.01 0.13±0.03 0.08±0.01 0.292 
CAST 4.19±0.53 3.93±0.41 5.01±0.35 4.25±0.44 0.374 
CTSB 30.61±2.51 33.9±3.15 37.67±3.65 33.74±4.19 0.593 
CTSD 4.67±1.50 4.14±1.02 2.69±0.54 3.16±0.23 0.461 
CTSL 86.43±10.19 77.26±10.64 77.91±9.76 74.30±12.19 0.875 
CTSS 2.12±0.12 2.38±0.35 2.65±0.32 2.44±0.28 0.635 
PSMD4 2.53±0.26 2.06±0.22 2.64±0.12 2.03±0.24 0.142 
PSD12 3.59±0.30 3.70±0.34 4.20±0.33 3.10±0.39 0.184 
PSMA5 3.31±0.34 2.47±0.50 3.91±0.37 2.68±0.60 0.174 










UBE2A 2.15±0.26 1.73±0.11 1.98±0.13 2.10±0.18 0.407 
UBE2D2 6.00±0.37 4.92±0.32 4.76±0.22 5.04±0.48 0.118 
UBE2L3 12.31±0.86 10.04±0.63 12.95±0.64 10.28±1.07 0.059 
UBE2N 3.83±0.15 3.23±0.26 3.86±0.07 3.56±0.42 0.373 
CUL2 1.06±0.09 0.91±0.06 1.06±0.06 0.94±0.07 0.331 
CUL3 0.99±0.08 0.86±0.07 0.98±0.06 0.81±0.05 0.140 


































 D1 D2 D3 D4 P-value 
Hsp90β 185.3±3.99a 134.4±7.32b 149.7±7.70b 133.67±4.38b <0.001 
GRP-170 6.10±0.62 5.80±0.76 6.36±0.42 4.85±0.44 0.268 
GRP-94 15.10±2.50 13.20±1.81 11.78±1.51 9.33±0.72 0.118 
DER-1 11.09±0.70 10.09±0.91 10.38±0.62 8.72±0.79 0.185 
IL-1β 0.01±0.01 0.01±0.01 0.03±0.01 0.01±0.01 0.325 
IL-1R1 2.36±0.26 2.46±0.28 3.50±0.80 3.63±0.94 0.206 
IL-1R2 0.01±0.01 0.01±0.01 0.04±0.02 0.01±0.01 0.053 










IL-8 0.03±0.01 0.03±0.01 0.04±0.01 0.03±0.01 0.463 
IL-8RA 0.15±0.03 0.14±0.04 0.22±0.07 0.15±0.04 0.576 
IL-10 0.05±0.01 0.04±0.01 0.04±0.01 0.03±0.01 0.613 




















SIRT1 0.51±0.03 0.53±0.04 0.57±0.06 0.55±0.04 0.764 
SIRT2 2.01±0.13 1.80±0.15 1.81±0.06 1.77±0.16 0.598 
SIRT3 0.34±0.03 0.30±0.04 0.35±0.03 0.23±0.01 0.300 
SIRT4 0.14±0.01 0.13±0.01 0.13±0.01 0.13±0.01 0.738 
SIRT5 2.14±0.16 1.86±0.17 1.73±0.13 1.72±0.15 0.217 
PGC1α 0.18±0.03 0.19±0.03 0.17±0.03 0.22±0.04 0.812 










ND2 184.9±9.65 182.6±18.13 235.7±17.7 204.4±20.76 0.161 










SCO1 0.49±0.06 0.43±0.05 0.44±0.02 0.35±0.03 0.136 
UCP1 108.0±11.71 92.37±20.75 109.8±14.42 112.3±13.36 0.795 
UCP2 0.02±0.01 0.01±0.01 0.01±0.01 0.01±0.01 0.300 
LXRα 5.66±0.78a 3.34±0.33b 4.62±0.41ab 4.10±0.36ab 0.038 
PPARα 16.77±1.13 14.43±2.06 19.06±1.70 16.42±1.36 0.276 
PPARγ 5.50±0.57a 3.79±0.55b 3.95±0.17b 3.86±0.37b 0.037 
Table S5. Relative gene expression of growth-related genes in the skeletal muscle of gilthead sea bream sampled in 
August 2013 (week 13). Data are the mean ± SEM of 6-7 fish. All data are referenced to the expression level of IGFR2 
of control fish (D1 diet) with an arbitrarily assigned value of 1. Different superscript letters in each row indicate 
significant differences among dietary treatments (SNK test, P<0.05). 
 D1 D2 D3 D4 P-value 
GHR-I 8.22±0.46 7.12±0.96 6.81±0.58 7.52±0.55 0.480 
GHR-II 3.63±0.37 2.60±0.37 2.96±0.76 2.55±0.50 0.501 
IGF-I 0.59±0.06 0.65±0.13 0.69±0.09 0.61±0.04 0.789 
IGF-II 3.2±0.32 3.21±0.28 3.11±0.26 2.76±0.36 0.705 
IGFBP1 0.31±0.05 0.40±0.05 0.45±0.05 0.31±0.05 0.062 
IGFBP4 0.49±0.07 0.67±0.15 0.45±0.05 0.70±0.17 0.419 
IGFBP7 4.61±0.53 4.31±0.47 3.97±0.29 3.61±0.67 0.540 
INSR 1.44±0.09 1.21±0.07 1.42±0.09 1.31±0.16 0.451 
IGFR1 1.41±0.12 1.17±0.12 1.27±0.07 1.17±0.13 0.384 










MyoD2 8.04±1.16 7.02±1.01 8.75±1.18 6.83±0.78 0.517 
Myf5 1.05±0.09 1.07±0.06 1.12±0.05 0.97±0.08 0.544 
Myf6 1.03±0.09 0.96±0.07 1.23±0.04 1.08±0.22 0.530 
MSTN 5.21±1.35 4.51±0.45 6.17±1.82 5.70±0.96 0.493 
MEF2A 36.17±2.2 34.08±1.95 39.18±2.17 37.30±3.13 0.543 
MEF2C 8.77±0.44 7.80±0.42 8.55±0.51 8.09±0.57 0.523 
FST 0.84±0.15 0.88±0.22 0.88±0.03 0.89±0.20 0.995 
CAV3 73.81±4.50 71.88±2.71 87.10±6.41 77.70±3.76 0.128 










PCNA 2.73±0.29 2.57±0.20 3.00±0.20 2.26±0.26 0.204 
PAX7 0.12±0.01 0.15±0.02 0.14±0.02 0.15±0.01 0.383 
SOX3 0.06±0.03 0.02±0.01 0.04±0.01 0.03±0.01 0.690 
MET 0.37±0.04 0.34±0.04 0.33±0.03 0.26±0.02 0.145 
CAPN1 3.92±0.22 3.91±0.34 4.21±0.30 3.85±0.29 0.808 










CAST 13.91±1.15 11.21±0.50 14.24±1.83 12.36±0.87 0.312 
CTSB 7.12±0.58 7.19±0.45 5.98±0.37 6.10±0.69 0.262 
CTSD 0.91±0.07 0.96±0.06 0.86±0.05 0.73±0.09 0.151 
CTSL 11.36±0.90 11.32±1.19 10.78±0.65 10.22±0.79 0.776 
CTSS 2.04±0.27 2.32±0.24 1.74±0.30 1.57±0.23 0.224 
PSMD4 1.97±0.10 1.92±0.05 2.11±0.08 1.75±0.17 0.179 




























UBE2A 4.29±0.86 3.46±0.14 3.69±0.35 3.06±0.27 0.389 
UBE2D2 1.98±0.19 1.92±0.07 2.16±0.17 1.61±0.12 0.091 
  D1 D2 D3 D4 P-value 




















CUL5 0.68±0.07 0.67±0.04 0.81±0.11 0.60±0.06 0.228 
mtHsp10 5.39±0.79 5.60±0.63 6.83±0.84 4.86±0.67 0.300 
Hsp30 0.08±0.06 0.08±0.02 0.11±0.07 0.08±0.04 0.966 
mtHsp60 2.10±0.19 2.17±0.19 2.58±0.22 1.85±0.20 0.110 
mtHsp70 4.44±0.38 4.21±0.30 5.40±0.49 4.48±0.38 0.197 
Hsp90α 60.02±8.51 69.10±8.46 73.07±8.37 57.80±3.82 0.434 
Hsp90β 29.87±2.55 31.26±2.86 31.34±2.05 27.65±2.45 0.690 
GRP-170 1.83±0.15 1.81±0.13 1.98±0.09 1.60±0.16 0.282 
GRP-94 3.23±0.29 3.04±0.16 2.96±0.26 2.41±0.14 0.085 
DER-1 9.18±0.55 9.48±0.37 10.84±0.67 8.76±0.60 0.079 
IL-1β 0.05±0.01 0.04±0.01 0.05±0.01 0.05±0.01 0.659 
IL-1R1 0.61±0.04 0.62±0.09 0.55±0.06 0.47±0.07 0.367 
IL-1R2 0.02±0.01 0.02±0.01 0.01±0.01 0.01±0.01 0.086 
IL-6 0.01±0.01 0.01±0.01 0.01±0.01 0.01±0.01 0.456 
IL-6RA 0.44±0.03 0.44±0.07 0.47±0.02 0.38±0.06 0.596 
IL-6RB 2.91±0.16 2.87±0.12 3.01±0.21 2.40±0.22 0.122 
IL-8 0.04±0.01 0.04±0.01 0.04±0.01 0.04±0.01 0.787 
IL-10 0.05±0.01 0.06±0.01 0.05±0.01 0.04±0.01 0.356 
IL-10RA 0.06±0.01 0.06±0.01 0.05±0.01 0.04±0.01 0.438 
IL-10RB 0.73±0.05 0.91±0.05 0.76±0.04 0.73±0.08 0.125 
TNFα 0.10±0.01ab 0.10±0.01ab 0.12±0.01b 0.08±0.01a 0.025 
TRADD 0.29±0.02 0.32±0.03 0.34±0.02 0.27±0.03 0.251 
SIRT1 0.61±0.04 0.61±0.02 0.61±0.02 0.55±0.06 0.672 
SIRT2 1.27±0.11 1.19±0.04 1.26±0.07 1.06±0.11 0.314 
SIRT3 0.17±0.01 0.17±0.02 0.19±0.02 0.15±0.01 0.310 
SIRT4 0.14±0.01 0.12±0.01 0.14±0.01 0.12±0.01 0.254 
SIRT5 1.89±0.15 1.74±0.13 1.95±0.08 1.64±0.12 0.282 
PGC1α 0.32±0.09 0.24±0.08 0.28±0.06 0.32±0.10 0.896 
CPT1A 5.66±0.59 5.16±0.66 4.50±0.36 6.52±0.99 0.226 
CS 42.9±3.49 38.41±2.72 40.39±2.24 39.05±3.97 0.769 
ND2 182.3±24.2 224.6±11.9 231.1±26.5 205.0±14.1 0.354 
NDUFAF2 2.09±0.15 2.00±0.11 2.04±0.14 1.80±0.15 0.462 
COXI 553.6±72.1 503.9±22.8 551.4±24.6 503.8±11.4 0.711 
SCO1 0.32±0.03 0.29±0.02 0.31±0.03 0.33±0.04 0.812 
UCP2 0.64±0.10 0.61±0.09 0.91±0.18 0.72±0.16 0.365 
UCP3 14.36±2.62 13.30±3.07 20.36±2.42 16.72±3.42 0.363 
LXRα 0.72±0.05 0.70±0.02 0.65±0.04 0.60±0.04 0.137 
PPARα 1.98±0.10a 1.80±0.12ab 1.64±0.11ab 1.37±0.16b 0.013 
PPARγ 1.64±0.14a 1.62±0.48ab 1.32±0.24ab 1.10±0.10b 0.015 
 
